

JOHN J. FASO
19TH DISTRICT, NEW YORK

1616 LONGWORTH HOUSE OFFICE BUILDING
WASHINGTON, DC 20515
(202) 225-5614

<http://faso.house.gov>



Congress of the United States
House of Representatives

COMMITTEE ON AGRICULTURE
SUBCOMMITTEE ON COMMODITY EXCHANGES,
ENERGY, AND CREDIT

SUBCOMMITTEE ON NUTRITION

COMMITTEE ON THE BUDGET

COMMITTEE ON TRANSPORTATION
AND INFRASTRUCTURE

VICE CHAIR, SUBCOMMITTEE ON
RAILROADS, PIPELINES, AND HAZARDOUS MATERIALS

SUBCOMMITTEE ON ECONOMIC DEVELOPMENT,
PUBLIC BUILDINGS, AND EMERGENCY MANAGEMENT

SUBCOMMITTEE ON HIGHWAYS AND TRANSIT

May 10, 2018

Dr. Scott Gottlieb
Commissioner of Food and Drugs
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993

Dear Commissioner Gottlieb,

I thank you for adding various epinephrine auto-injectors to the FDA's list of existing drug shortages. This shortage has been noticed in New York State's Hudson Valley and Catskill regions, which I represent in Congress.

Can you provide further detail as to when this shortage is expected to end? Further, what actions are currently being undertaken by the FDA to guarantee access to epinephrine auto-injectors? Many of my constituents rely on auto-injectors to treat allergic reactions and not having access to these products presents a considerable risk to their health.

Additionally, is the FDA working to allow or expand access to other auto-injector products not currently approved for sale in the U.S.? According to various media reports, alternatives such as Jext by ALK-Abelló and Emenade by Bausch and Lomb, which are currently available in various European Union countries and the United Kingdom, could help to lower costs for American consumers and to prevent future shortages if allowed to enter the U.S. market.

Thank you for your time and attention on this important issue. Please feel free to contact me to discuss this matter further.

Sincerely,

John J. Faso
Member of Congress